JP2002516061A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002516061A5 JP2002516061A5 JP2000516019A JP2000516019A JP2002516061A5 JP 2002516061 A5 JP2002516061 A5 JP 2002516061A5 JP 2000516019 A JP2000516019 A JP 2000516019A JP 2000516019 A JP2000516019 A JP 2000516019A JP 2002516061 A5 JP2002516061 A5 JP 2002516061A5
- Authority
- JP
- Japan
- Prior art keywords
- thymidine kinase
- enzyme
- nucleic acid
- acid molecule
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000006601 Thymidine Kinase Human genes 0.000 description 78
- 108020004440 Thymidine kinase Proteins 0.000 description 78
- 102000039446 nucleic acids Human genes 0.000 description 39
- 108020004707 nucleic acids Proteins 0.000 description 39
- 150000007523 nucleic acids Chemical class 0.000 description 39
- 239000002777 nucleoside Substances 0.000 description 35
- 230000035772 mutation Effects 0.000 description 34
- -1 DRH nucleoside Chemical class 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 19
- 108090000790 Enzymes Proteins 0.000 description 19
- 241000700586 Herpesviridae Species 0.000 description 18
- 150000003833 nucleoside derivatives Chemical class 0.000 description 17
- 238000006467 substitution reaction Methods 0.000 description 16
- 125000003275 alpha amino acid group Chemical group 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 108020004202 Guanylate Kinase Proteins 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 102000006638 guanylate kinase Human genes 0.000 description 12
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000007923 virulence factor Effects 0.000 description 9
- 239000000304 virulence factor Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 6
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 6
- 229960004150 aciclovir Drugs 0.000 description 6
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 229960002963 ganciclovir Drugs 0.000 description 6
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 6
- 229960004716 idoxuridine Drugs 0.000 description 6
- 229940113082 thymine Drugs 0.000 description 6
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N trifluridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C(F)(F)F)=C1 VSQQQLOSPVPRAZ-RRKCRQDMSA-N 0.000 description 6
- 229960003962 trifluridine Drugs 0.000 description 6
- 229960000523 zalcitabine Drugs 0.000 description 6
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 5
- 230000000865 phosphorylative effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 101000614191 Homo sapiens Guanylate kinase Proteins 0.000 description 2
- 101001139305 Mus musculus Guanylate kinase Proteins 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- VUFVGYBIFMCJPB-UHFFFAOYSA-N 1-iodopyrimidine-2,4-dione Chemical compound IN1C=CC(=O)NC1=O VUFVGYBIFMCJPB-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108090000472 Phosphoenolpyruvate carboxykinase (ATP) Proteins 0.000 description 1
- 102100034792 Phosphoenolpyruvate carboxykinase [GTP], mitochondrial Human genes 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6181297P | 1997-10-14 | 1997-10-14 | |
| US60/061,812 | 1997-10-14 | ||
| PCT/US1998/021672 WO1999019466A2 (en) | 1997-10-14 | 1998-10-14 | Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008176378A Division JP5070145B2 (ja) | 1997-10-14 | 2008-07-04 | チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002516061A JP2002516061A (ja) | 2002-06-04 |
| JP2002516061A5 true JP2002516061A5 (https=) | 2006-01-05 |
Family
ID=22038301
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000516019A Withdrawn JP2002516061A (ja) | 1997-10-14 | 1998-10-14 | チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質 |
| JP2008176378A Expired - Fee Related JP5070145B2 (ja) | 1997-10-14 | 2008-07-04 | チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質 |
| JP2012000673A Withdrawn JP2012115270A (ja) | 1997-10-14 | 2012-01-05 | チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008176378A Expired - Fee Related JP5070145B2 (ja) | 1997-10-14 | 2008-07-04 | チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質 |
| JP2012000673A Withdrawn JP2012115270A (ja) | 1997-10-14 | 2012-01-05 | チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (7) | US7888114B2 (https=) |
| EP (3) | EP2386629A1 (https=) |
| JP (3) | JP2002516061A (https=) |
| AT (1) | ATE374247T1 (https=) |
| CA (1) | CA2306443A1 (https=) |
| DE (1) | DE69838483T2 (https=) |
| WO (1) | WO1999019466A2 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69838483T2 (de) * | 1997-10-14 | 2008-07-03 | Darwin Molecular Corp. | Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten |
| GB0008966D0 (en) | 2000-04-13 | 2000-05-31 | Imp College Innovations Ltd | Vectors for gene therapy |
| GB0010105D0 (en) * | 2000-04-26 | 2000-06-14 | Ml Lab Plc | Cell ablation |
| EP1283874A2 (en) * | 2000-05-12 | 2003-02-19 | Wolfgang Knecht | Novel deoxynucleoside kinase enzyme variants |
| US6849407B2 (en) | 2000-08-31 | 2005-02-01 | Mayo Foundation For Medical Education And Research | Detection of varicella-zoster virus |
| AU2002243751A1 (en) | 2001-01-31 | 2002-08-12 | Mayo Foundation For Medical Education And Research | Detection of herpes simplex virus |
| US7691571B2 (en) | 2001-01-31 | 2010-04-06 | Mayo Foundation For Medical Education And Research | Detection of bordetella |
| US7439271B2 (en) * | 2001-06-27 | 2008-10-21 | The Gillette Company | Reduction of hair growth |
| WO2003100045A1 (en) * | 2002-05-23 | 2003-12-04 | Wolfgang Knecht | Plant thymidine kinases and their use |
| DE60325587D1 (de) | 2002-05-23 | 2009-02-12 | Wolfgang Knecht | Thymidinkinasen aus pflanzen und ihre verwendung |
| US7074598B2 (en) | 2002-09-25 | 2006-07-11 | Mayo Foundation For Medical Education And Research | Detection of vancomycin-resistant enterococcus spp. |
| US7365176B2 (en) | 2002-09-26 | 2008-04-29 | Mayo Foundation For Medical Education And Research | Detection of Epstein-Barr virus |
| US7074599B2 (en) | 2002-09-27 | 2006-07-11 | Mayo Foundation For Medical Education And Research | Detection of mecA-containing Staphylococcus spp. |
| US7427475B2 (en) | 2003-11-18 | 2008-09-23 | Mayo Foundation For Medical Education And Research | Detection of group B streptococcus |
| GB0413702D0 (en) | 2004-06-18 | 2004-07-21 | Molmed Spa | Thymidine kinase |
| EA201490568A1 (ru) | 2011-09-06 | 2014-06-30 | Новозимс А/С | Варианты глюкоамилазы и кодирующие их полинуклеотиды |
| EP3988671A1 (en) | 2013-02-20 | 2022-04-27 | Emory University | Compositions for sequencing nucleic acids in mixtures |
| ES2703341T3 (es) | 2013-03-14 | 2019-03-08 | Genvivo Inc | Ensayo diagnóstico de timidina quinasa para aplicaciones de terapia génica |
| EP3003022B1 (en) | 2013-06-04 | 2017-11-22 | Virginia Commonwealth University | Use of a truncated ccn1 promoter for cancer diagnostics, therapeutics and theranostics |
| EP3004872B1 (en) | 2013-06-04 | 2017-10-18 | Virginia Commonwealth University | Mda-9/syntenin promoter to image and treat metastatic cancer cells |
| US9951114B2 (en) | 2013-06-04 | 2018-04-24 | Virginia Commonwealth University | Recombinant cancer therapeutic cytokine |
| US9454494B2 (en) * | 2014-08-01 | 2016-09-27 | Honeywell International Inc. | Encrypting a communication from a device |
| EP4400516A1 (en) | 2014-12-15 | 2024-07-17 | The Regents of the University of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
| EP3234120B1 (en) | 2014-12-15 | 2025-09-03 | The Regents of the University of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
| DK3368571T5 (da) | 2015-10-30 | 2024-09-30 | Univ California | Transformerende, vækstfaktor-beta-responsive polypeptider og fremgangsmåder til anvendelse deraf |
| EP3478325B1 (en) | 2016-07-01 | 2024-07-17 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
| JP2019530440A (ja) | 2016-09-02 | 2019-10-24 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インターロイキン６受容体α結合単鎖可変断片を含む方法および組成物 |
| WO2019108777A1 (en) * | 2017-11-29 | 2019-06-06 | Research Development Foundation | Elimination of proliferating cells from stem cell-derived grafts |
| WO2019200013A1 (en) | 2018-04-11 | 2019-10-17 | Cancer Targeting Systems, Inc. | Therapeutic constructs for treating cancer |
| JP2022520220A (ja) * | 2019-02-14 | 2022-03-29 | イグナイト イミュノセラピー インク | 組換えワクシニアウイルスおよびその使用方法 |
| CN109735571A (zh) * | 2019-03-11 | 2019-05-10 | 四川药智联恒科技有限公司 | 双自杀基因慢病毒表达载体及其应用 |
| WO2023076177A2 (en) * | 2021-10-25 | 2023-05-04 | Genvivo, Inc. | Compositions and methods for therapeutic delivery |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018884A (en) | 1975-06-26 | 1977-04-19 | Hoffmann-La Roche Inc. | Fluorogenic materials and labeling techniques |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4769331A (en) | 1981-09-16 | 1988-09-06 | University Patents, Inc. | Recombinant methods and materials |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4514497B1 (en) | 1983-12-30 | 1998-02-24 | Novagene Inc | Modified live pseudorabies viruses |
| US4859587A (en) | 1984-06-04 | 1989-08-22 | Institut Merieux | Recombinant herpes simplex viruses, vaccines and methods |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| US4801542A (en) | 1984-10-12 | 1989-01-31 | Zymogenetics, Inc. | Expression of biologically active PDGF analogs in eucaryotic cells |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| US4897255A (en) | 1985-01-14 | 1990-01-30 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| GR860984B (en) | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
| US4744981A (en) | 1985-10-17 | 1988-05-17 | Neorx Corporation | Trichothecene antibody conjugates |
| US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
| US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
| US4851341A (en) | 1986-12-19 | 1989-07-25 | Immunex Corporation | Immunoaffinity purification system |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5643758A (en) * | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| EP0329184A3 (en) | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
| US4988496A (en) | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| JP2752788B2 (ja) | 1989-01-23 | 1998-05-18 | カイロン コーポレイション | 感染および過剰増殖障害の為の組換え療法 |
| GB8914543D0 (en) | 1989-06-23 | 1989-08-09 | Parker David | Chemical compounds |
| JP4041535B2 (ja) | 1989-08-18 | 2008-01-30 | オックスフォード バイオメディカ（ユーケー）リミテッド | 標的細胞にベクター構造体を運搬する組換レトロウィルス |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
| US5203975A (en) | 1991-10-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Process for cathodic electrodeposition of a clear coating over a conductive paint layer |
| WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
| GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
| EP0650370A4 (en) | 1992-06-08 | 1995-11-22 | Univ California | METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES. |
| CA2137361A1 (en) | 1992-06-10 | 1993-12-23 | W. French Anderson | Vector particles resistant to inactivation by human serum |
| GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
| WO1994014971A1 (en) | 1992-12-23 | 1994-07-07 | Arch Development Corporation | Synthetic herpes simplex virus promoters |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| WO1995004139A1 (en) | 1993-07-27 | 1995-02-09 | The Wistar Institute Of Anatomy And Biology | Modified dna virus vectors and uses therefor |
| ES2328424T3 (es) | 1993-09-15 | 2009-11-12 | Novartis Vaccines And Diagnostics, Inc. | Vectores de alfavirus recombinantes. |
| FR2712603B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
| US5877010A (en) | 1994-05-02 | 1999-03-02 | University Of Washington | Thymidine kinase mutants |
| FR2723962B1 (fr) * | 1994-08-25 | 1996-10-31 | Univ Paris Curie | Hsv1-tk modifiee fonctionnelle |
| SK107998A3 (en) * | 1996-02-09 | 1999-01-11 | Rhone Poulenc Rorer Sa | Variants of thymidine kinase, related nucleic acids sequences and their use in genic therapy |
| FR2746016B1 (fr) * | 1996-03-15 | 1998-04-17 | Combinaisons d'enzymes pour la destruction de cellules proliferatives | |
| DE69838483T2 (de) * | 1997-10-14 | 2008-07-03 | Darwin Molecular Corp. | Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten |
-
1998
- 1998-10-14 DE DE69838483T patent/DE69838483T2/de not_active Expired - Lifetime
- 1998-10-14 EP EP10182771A patent/EP2386629A1/en not_active Withdrawn
- 1998-10-14 WO PCT/US1998/021672 patent/WO1999019466A2/en not_active Ceased
- 1998-10-14 EP EP10182819A patent/EP2386630A1/en not_active Withdrawn
- 1998-10-14 CA CA002306443A patent/CA2306443A1/en not_active Abandoned
- 1998-10-14 EP EP98953487A patent/EP1025212B1/en not_active Expired - Lifetime
- 1998-10-14 AT AT98953487T patent/ATE374247T1/de not_active IP Right Cessation
- 1998-10-14 JP JP2000516019A patent/JP2002516061A/ja not_active Withdrawn
-
2008
- 2008-07-04 JP JP2008176378A patent/JP5070145B2/ja not_active Expired - Fee Related
-
2009
- 2009-05-08 US US12/463,283 patent/US7888114B2/en not_active Expired - Fee Related
- 2009-05-08 US US12/463,261 patent/US7888091B2/en not_active Expired - Fee Related
-
2010
- 2010-12-29 US US12/981,418 patent/US8163528B2/en not_active Expired - Fee Related
- 2010-12-29 US US12/981,428 patent/US8236541B2/en not_active Expired - Fee Related
-
2011
- 2011-11-30 US US13/308,188 patent/US20120142071A1/en not_active Abandoned
- 2011-11-30 US US13/308,164 patent/US20120149890A1/en not_active Abandoned
-
2012
- 2012-01-05 JP JP2012000673A patent/JP2012115270A/ja not_active Withdrawn
- 2012-06-29 US US13/538,503 patent/US20130011903A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002516061A5 (https=) | ||
| Johansson et al. | Cloning and expression of human deoxyguanosine kinase cDNA. | |
| AU2020203408B2 (en) | Improved thymidine kinase gene | |
| US6207150B1 (en) | Variants of thymidine kinase, nucleic acids encoding them, and methods of using them | |
| JP4672659B2 (ja) | 改善されたシトシンデアミナーゼ活性を有するポリペプチド | |
| JP2013209415A (ja) | 哺乳類における抗腫瘍または抗ウイルス治療を行う目的において設計された要素のキット | |
| RU2297453C2 (ru) | Вариант мультисубстратной дезоксирибонуклеозидкиназы, кодирующий его мутированный полинуклеотид, экспрессирующая векторная конструкция и их применение | |
| CZ291398A3 (cs) | Kombinace enzymů pro destrukci proliferativních buněk | |
| US7666639B2 (en) | Plant deoxyribonucleoside kinase enzymes and their use | |
| Wiebe et al. | Enzyme-targeted, nucleoside-based radiopharmaceuticals for scintigraphic monitoring of gene transfer and expression | |
| TW202325851A (zh) | 用於治療劑遞送之組合物及方法 | |
| US7928206B2 (en) | Pharmaceutical composition comprising a thymidine kinase polynucleotide | |
| Marx | Gene Therapy—So Near and Yet So Far Away: Genes transferred into cultured cells often work very well but getting good expression offoreign genes in live animals is another matter | |
| US20070202120A1 (en) | Yellow Fever Mosquito Deoxyribonucleoside Kinases And Its Use | |
| Johner | The thymidine kinase of Epstein-Barr virus and herpes simplex virus and their application as suicide genes | |
| MXPA98007181A (en) | Combinations of enzymes for the destruction of proliferati cells |